Trial record 1 of 1 for:
C1973-203
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03217591 |
|
Recruitment Status :
Completed
First Posted : July 14, 2017
Last Update Posted : February 5, 2021
|
Sponsor:
Cyclerion Therapeutics
Information provided by (Responsible Party):
Cyclerion Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
To evaluate the safety and efficacy of IW-1973 in patients with type 2 diabetes mellitus with albuminuria who are on a stable regimen of renin-angiotensin system inhibitors.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Type 2 Diabetes Mellitus With Diabetic Nephropathy | Drug: IW-1973 Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 156 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Phase 2, randomized, double-blind, placebo-controlled, parallel-group study |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of IW-1973 in Patients With Type 2 Diabetes With Albuminuria Treated With Renin-Angiotensin System Inhibitors |
| Actual Study Start Date : | August 1, 2017 |
| Actual Primary Completion Date : | August 20, 2019 |
| Actual Study Completion Date : | August 20, 2019 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Type 2 diabetes
| Arm | Intervention/treatment |
|---|---|
|
Experimental: IW-1973 Low Dose
Administered daily for 12 weeks
|
Drug: IW-1973
Oral Tablet |
|
Experimental: IW-1973 High Dose
Administered daily for 12 weeks
|
Drug: IW-1973
Oral Tablet |
|
Placebo Comparator: Placebo
Placebo to match experimental drug administered daily for 12 weeks
|
Drug: Placebo
Oral Tablet |
Primary Outcome Measures :
- Incidence of Treatment-Emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs. [ Time Frame: From Randomization through Follow-Up Visit (Day 115 ± 3 days) ]
- Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Weeks 8 and 12. [ Time Frame: (Baseline, Week 8, Week 12) ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 25 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- Patient is an ambulatory male or female from 25 to 75 years old at the Screening Visit.
- Patient has type 2 diabetes diagnosed by a physician or nurse practitioner ≥6 months before the Screening Visit, has been on ≥1 antihyperglycemic medication for ≥12 weeks preceding the Randomization Visit, and has been on a stable regimen (ie, same drug and same dose) of ≥1 antihyperglycemic medication for ≥28 days preceding the Randomization Visit. (Modification of short-acting insulin throughout the Screening Period will not affect eligibility.)
- Patient has been on a stable regimen (ie, same drug and dose) of antihypertensive medications, which must include an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB), for ≥28 days preceding the Randomization Visit and is expected to remain on their regimen through the Follow-up Visit.
-
Patient has the following:
- Estimated glomerular filtration rate (eGFR) 30 to 75 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation (1) at the Screening and Baseline Visits
- Urine albumin-to-creatinine ratio (UACR) >200 mg/g at the Screening and Baseline Visits and <5000 mg/g at Screening and Baseline Visits
- Serum albumin >3.0 g/dL at the Screening and Baseline Visits
- Hemoglobin A1c (HbA1c) ≤11% at the Screening and Baseline Visits
- Systolic blood pressure (BP) of 110 to 160 mm Hg at the Screening and Baseline Visits
- Women of childbearing potential must have a negative pregnancy test prior to randomization and must agree to use protocol-specified contraception from the Screening Visit through 60 days after the final dose of study drug.
- Male patients must be surgically sterile by vasectomy (conducted ≥60 days before the Screening Visit or confirmed via sperm analysis) or must agree to use protocol-specified contraception from the Screening Visit through 60 days after the final dose of study drug.
- Other inclusion criteria per protocol.
Key Exclusion Criteria:
- Patient has a history of secondary hypertension (ie, renal artery stenosis, primary aldosteronism, or pheochromocytoma).
- Patient has a body mass index (BMI) <20 or >45 kg/m2 at the Screening Visit.
- Patient has a history of platelet dysfunction, hemophilia, von Willebrand disease, coagulation disorder, other bleeding diathesis, or significant, nontraumatic bleeding episode(s), such as from a gastrointestinal source.
- Patient has hepatic impairment defined as Child-Pugh A, B, C.
- Patient has significant comorbidities (eg, malignancy, advanced liver disease, pulmonary hypertension, pulmonary fibrosis, lung disease requiring supplemental oxygen) or other significant conditions that, in the Investigator's opinion, would limit the patient's ability to complete or participate in this clinical study; has been hospitalized for cardiovascular, renal, or metabolic cause in the 3 months before the Screening Visit; or has a life expectancy of less than 1 year.
- Patient has had prior dialysis, renal transplant, or planned renal transplant.
-
Patient has clinically active, symptomatic, or unstable coronary artery or heart disease within the 3 months before the Screening Visit, defined as 1 of the following:
- Hospitalization for myocardial infarction (MI), unstable angina, or heart failure
- New-onset angina with positive functional study or coronary angiogram revealing stenosis
- Coronary revascularization procedure
- Patient has a history of clinically significant hypersensitivity or allergies to any of the inactive ingredients contained in the active or placebo drug products.
- Patient has previously received IW-1973 in a study, or received an investigational drug during the 30 days or 5 half-lives of that investigational drug (whichever is longer) before the Screening Visit, or is planning to receive another investigational drug at any time during the study.
- Patient is taking specific inhibitors of phosphodiesterase 5 (PDE5), nonspecific inhibitors of PDE5 (including dipyridamole and theophylline), any supplements for the treatment of erectile dysfunction, riociguat, or nitrates or nitric oxide (NO) donors in any form. These medications and supplements are prohibited from 7 days before Randomization through the duration of the study.
- Patient is taking strong cytochrome P450 3A (CYP3A) inhibitors (eg, ketoconazole, indinavir, nelfinavir, ritonavir, saquinavir, clarithromycin, telithromycin, itraconazole, and nefazodone). These medications are prohibited 14 days before Randomization through the duration of the trial.
- Other exclusion criteria per protocol.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03217591
Locations
Show 54 study locations
Sponsors and Collaborators
Cyclerion Therapeutics
Investigators
| Study Director: | John Hanrahan, MD MPH | Cyclerion Therapeutics, Inc. |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Cyclerion Therapeutics |
| ClinicalTrials.gov Identifier: | NCT03217591 |
| Other Study ID Numbers: |
C1973-203 |
| First Posted: | July 14, 2017 Key Record Dates |
| Last Update Posted: | February 5, 2021 |
| Last Verified: | February 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Kidney Diseases Diabetic Nephropathies Albuminuria Diabetes Mellitus, Type 2 Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Urologic Diseases |
Diabetes Complications Proteinuria Urination Disorders Urological Manifestations Praliciguat Guanylyl Cyclase C Agonists Enzyme Activators Molecular Mechanisms of Pharmacological Action Gastrointestinal Agents |